Formulation: A solid
Formal Name: (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-(phenyl-d5)-2(1H)-isoquinolinecarboxylate, butanedioic acid
Purity: ≥99% deuterated forms (d1-d5)
Formula Markup: C23H21D5N2O2 • C4H6O4
Formula Weight: 485,6
Shelf life (days): 1460
Notes: Solifenacin-d5 is intended for use as an internal standard for the quantification of solifenacin (Item No. 17320) by GC- or LC-MS. Solifenacin is a competitive antagonist of M1, M2, and M3 muscarinic acetylcholine receptors (Kis = 25, 125, and 10 nM, respectively, for the human receptors).{28353} It inhibits calcium mobilization induced by carbamoylcholine (carbachol; Item No. 14486) in isolated guinea pig detrusor muscle cells (Ki = 4 nM).{48902} Solifenacin inhibits carbachol-induced contraction of isolated guinea pig urinary bladder smooth muscle. In vivo, solifenacin (0.03-1 mg/kg) inhibits carbachol-induced increases in urinary bladder pressure in anesthetized rats. Formulations containing solifenacin have been used in the treatment of overactive bladder.